Limits...
Evidence produced in Japan: tegafur-based preparations for postoperative chemotherapy in breast cancer.

Watanabe T - Breast Cancer (2013)

Bottom Line: UFT is an oral preparation that was designed to achieve and maintain high concentrations of 5-FU in plasma by combining tegafur, a prodrug of 5-FU, with uracil.UFT is characterized by mild adverse events, allowing long-term treatment.The prolonged maintenance of high plasma 5-FU concentrations has been suggested to inhibit micrometastases after surgery.

View Article: PubMed Central - PubMed

Affiliation: Department of Medicine, Hamamatsu Oncology Center, 3-6-13 Chuo, Naka-ku, Hamamatsu, Shizuoka, 430-0929, Japan, twatanab@oncoloplan.com.

ABSTRACT
Oral fluoropyrimidine anticancer agents (oral 5-fluorouracil [5-FU]) able to be used as chemotherapy for breast cancer include tegafur-uracil (UFT), tegafur-gimeracil-oteracil potassium (S-1), doxifluridine, and capecitabine. Since the 1980s, UFT has been most widely used for postoperative chemotherapy in breast cancer. UFT is an oral preparation that was designed to achieve and maintain high concentrations of 5-FU in plasma by combining tegafur, a prodrug of 5-FU, with uracil. UFT is characterized by mild adverse events, allowing long-term treatment. The prolonged maintenance of high plasma 5-FU concentrations has been suggested to inhibit micrometastases after surgery. Recently, large clinical trials conducted in Japan have shown that UFT-based postoperative chemotherapy is therapeutically useful in patients with node-negative (n0), high-risk breast cancer. We review the results of clinical trials of postoperative chemotherapy with UFT in Japan and discuss its roles and future prospects.

Show MeSH

Related in: MedlinePlus

Relapse-free survival according to estrogen receptor (ER) and age in the pooled analysis of N·SAS-BC01 trial and CUBC trial. HR hazard ratio
© Copyright Policy - OpenAccess
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3824200&req=5

Fig4: Relapse-free survival according to estrogen receptor (ER) and age in the pooled analysis of N·SAS-BC01 trial and CUBC trial. HR hazard ratio

Mentions: The results of a pooled analysis of the N·SAS-BC01 trial and the CUBC trial, both of which compared UFT with CMF, have been reported [11]. The noninferiority of UFT to CMF was not demonstrated statistically in the study group as a whole. In patients with ER-positive tumors, however, the noninferiority of UFT to CMF was statistically proven (hazard ratio of the UFT group to the CMF group, 0.79; 97.5 % CI 0.49–1.27). A subgroup analysis showed UFT was particularly more effective than CMF in patients 50 years or older who had ER-positive tumors (hazard ratio of the UFT group to the CMF group, 0.58; 95 % CI 0.34–1.01). These results suggested that UFT combined with endocrine therapy can effectively inhibit recurrence in patients with ER-positive breast cancer (Fig. 4).Fig. 4


Evidence produced in Japan: tegafur-based preparations for postoperative chemotherapy in breast cancer.

Watanabe T - Breast Cancer (2013)

Relapse-free survival according to estrogen receptor (ER) and age in the pooled analysis of N·SAS-BC01 trial and CUBC trial. HR hazard ratio
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3824200&req=5

Fig4: Relapse-free survival according to estrogen receptor (ER) and age in the pooled analysis of N·SAS-BC01 trial and CUBC trial. HR hazard ratio
Mentions: The results of a pooled analysis of the N·SAS-BC01 trial and the CUBC trial, both of which compared UFT with CMF, have been reported [11]. The noninferiority of UFT to CMF was not demonstrated statistically in the study group as a whole. In patients with ER-positive tumors, however, the noninferiority of UFT to CMF was statistically proven (hazard ratio of the UFT group to the CMF group, 0.79; 97.5 % CI 0.49–1.27). A subgroup analysis showed UFT was particularly more effective than CMF in patients 50 years or older who had ER-positive tumors (hazard ratio of the UFT group to the CMF group, 0.58; 95 % CI 0.34–1.01). These results suggested that UFT combined with endocrine therapy can effectively inhibit recurrence in patients with ER-positive breast cancer (Fig. 4).Fig. 4

Bottom Line: UFT is an oral preparation that was designed to achieve and maintain high concentrations of 5-FU in plasma by combining tegafur, a prodrug of 5-FU, with uracil.UFT is characterized by mild adverse events, allowing long-term treatment.The prolonged maintenance of high plasma 5-FU concentrations has been suggested to inhibit micrometastases after surgery.

View Article: PubMed Central - PubMed

Affiliation: Department of Medicine, Hamamatsu Oncology Center, 3-6-13 Chuo, Naka-ku, Hamamatsu, Shizuoka, 430-0929, Japan, twatanab@oncoloplan.com.

ABSTRACT
Oral fluoropyrimidine anticancer agents (oral 5-fluorouracil [5-FU]) able to be used as chemotherapy for breast cancer include tegafur-uracil (UFT), tegafur-gimeracil-oteracil potassium (S-1), doxifluridine, and capecitabine. Since the 1980s, UFT has been most widely used for postoperative chemotherapy in breast cancer. UFT is an oral preparation that was designed to achieve and maintain high concentrations of 5-FU in plasma by combining tegafur, a prodrug of 5-FU, with uracil. UFT is characterized by mild adverse events, allowing long-term treatment. The prolonged maintenance of high plasma 5-FU concentrations has been suggested to inhibit micrometastases after surgery. Recently, large clinical trials conducted in Japan have shown that UFT-based postoperative chemotherapy is therapeutically useful in patients with node-negative (n0), high-risk breast cancer. We review the results of clinical trials of postoperative chemotherapy with UFT in Japan and discuss its roles and future prospects.

Show MeSH
Related in: MedlinePlus